We are live on ! Find out more
EAM

Exome Asset Management Portfolio holdings

AUM $162M
1-Year Est. Return 259.04%
This Fund
S&P 500
This Quarter Est. Return
+28.52%
1 Year Est. Return
+259.04%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$162M
AUM Growth
-$31.2M
Cap. Flow
-$33.6M
Cap. Flow %
-20.7%
Top 10 Hldgs %
44.55%
Holding
71
New
15
Increased
1
Reduced
32
Closed
19

Top Buys

Rank Stock Value
1
TGTX icon
TG Therapeutics
TGTX
+$6.75M
2
ABVX
Abivax
ABVX
+$5.31M
3
AZN icon
AstraZeneca
AZN
+$2.27M
4
QURE icon
uniQure
QURE
+$2.12M
5
OCUL icon
Ocular Therapeutix
OCUL
+$1.65M

Top Sells

Rank Stock Value
1
PRAX icon
Praxis Precision Medicines
PRAX
+$5.78M
2
ELVN icon
Enliven Therapeutics
ELVN
+$5.09M
3
ELV icon
Elevance Health
ELV
+$4.3M
4
BBIO icon
BridgeBio Pharma
BBIO
+$3.44M
5
APLS
Apellis Pharmaceuticals
APLS
+$3.44M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CBIO
26
Crescent Biopharma
CBIO
$769M
$2.3M 1.42%
127,769
-25,422
-17% -$496K
AZN icon
27
AstraZeneca
AZN
$250B
$2.25M 1.39%
+12,045
New +$2.27M
BSX icon
28
Boston Scientific
BSX
$67B
$2.06M 1.27%
48,347
– –
ADAG
29
Adagene
ADAG
$238M
$2.05M 1.27%
488,293
-248,552
-34% -$935K
PEN icon
30
Penumbra
PEN
$12.6B
$1.99M 1.23%
6,300
– –
ISRG icon
31
Intuitive Surgical
ISRG
$126B
$1.95M 1.2%
4,908
-1,450
-23% -$633K
VKTX icon
32
Viking Therapeutics
VKTX
$4.02B
$1.87M 1.15%
+47,861
New +$1.55M
OCUL icon
33
Ocular Therapeutix
OCUL
$2.39B
$1.78M 1.1%
+181,588
New +$1.65M
EQ icon
34
Equillium
EQ
$147M
$1.77M 1.09%
+552,956
New +$1.32M
ASND icon
35
Ascendis Pharma A/S
ASND
$17.6B
$1.75M 1.08%
+6,573
New +$1.54M
CRBP icon
36
Corbus Pharmaceuticals
CRBP
$202M
$1.73M 1.07%
184,914
-49,222
-21% -$466K
CTMX icon
37
CytomX Therapeutics
CTMX
$791M
$1.73M 1.06%
460,067
-61,401
-12% -$234K
VSTM icon
38
Verastem
VSTM
$758M
$1.64M 1.01%
429,041
-207,659
-33% -$1M
NKTR icon
39
Nektar Therapeutics
NKTR
$2.59B
$1.56M 0.97%
+22,417
New +$1.64M
CLPT icon
40
ClearPoint Neuro
CLPT
$416M
$1.49M 0.92%
+83,636
New +$1.04M
INSM icon
41
Insmed
INSM
$27.4B
$1.48M 0.91%
13,873
-12,778
-48% -$1.55M
CAI
42
Caris Life Sciences
CAI
$7.15B
$1.39M 0.86%
+78,180
New +$1.4M
BBIO icon
43
BridgeBio Pharma
BBIO
$14.8B
$1.37M 0.84%
18,359
-49,133
-73% -$3.44M
ZBIO
44
Zenas BioPharma
ZBIO
$2.15B
$1.33M 0.82%
52,443
-28,287
-35% -$562K
NBP
45
NovaBridge Biosciences American Depositary Shares
NBP
$209M
$1.13M 0.69%
576,960
– –
ESTA icon
46
Establishment Labs
ESTA
$2.21B
$1.12M 0.69%
13,100
– –
RLAY icon
47
Relay Therapeutics
RLAY
$4.17B
$889K 0.55%
47,531
-230,771
-83% -$3.35M
GERN icon
48
Geron
GERN
$970M
$799K 0.49%
+624,046
New +$879K
DRUG
49
Bright Minds Biosciences
DRUG
$638M
$710K 0.44%
+10,110
New +$794K
CMPX icon
50
Compass Therapeutics
CMPX
$412M
$605K 0.37%
+276,165
New +$815K
1
2
3

Similar funds

STCOSD
Sageworth Trust Company of South Dakota Sioux Falls, South Dakota $162M AUM 26.79% 1-Year Est. Return
CCA
Cruiser Capital Advisors Stamford, Connecticut $162M AUM 78.28% 1-Year Est. Return
MIM
Macroview Investment Management Bethesda, Maryland $162M AUM 22.52% 1-Year Est. Return
CFG
Cornerstone Financial Group Omaha, Nebraska $162M AUM 14.64% 1-Year Est. Return
TF
TME Financial Huntington Beach, California $162M AUM 16.23% 1-Year Est. Return
CCM
Candelo Capital Management New York $162M AUM 112.87% 1-Year Est. Return
RWA
Reicon Wealth Advisors Atlanta, Georgia $162M AUM
VB
Value Base Tel Aviv, Israel $162M AUM 2.31% 1-Year Est. Return

Exome Asset Management's Q2 2026 Portfolio in Review

As of Q2 2026, Exome Asset Management held 71 positions worth $162M, down 16% from $193M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Exome Asset Management withdrew a net $33.6M in Q2 2026, closing 19 positions and reducing 32 holdings. Its most notable exit was Elevance Health, an estimated $4.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 88% a quarter earlier.

Against the trend, Exome Asset Management opened a new position in TG Therapeutics worth $9.06M.

  • Exome Asset Management's largest Q2 2026 buy was TG Therapeutics: 164,915 shares worth $9.06M.
  • Exome Asset Management added most to Maze Therapeutics in Q2 2026, an estimated $686K increase.
  • Exome Asset Management's biggest Q2 2026 reduction was Praxis Precision Medicines, cutting an estimated $5.78M.
  • Exome Asset Management fully exited Elevance Health in Q2 2026, selling an estimated $4.3M.
  • Exome Asset Management's ten largest holdings make up 45% of its $162M portfolio in Q2 2026.
  • Exome Asset Management opened 15 new positions and closed 19 in Q2 2026.
  • Exome Asset Management's portfolio value fell 16% quarter-over-quarter to $162M.

Based on Exome Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.